Cyclophosphamide versus Placebo in Scleroderma Lung Disease

P. Tashkin, Donald; M. Elashoff, Robert; J. Clements, Philip; Goldin, Jonathan; D. Roth, Michael; E. Furst, Daniel; Arriola, Edgar; M. Silver, Richard; Strange, Charlie; B. Bolster, Marcy; R. Seibold, James; Riley, D.; Hsu, Vivien; Varga, John; E. Schraufnagel, Dean; C. Theodore, Arthur; W. Simms, Robert; A. Wise, Robert; M. Wigley, Fredrick; White, Barbara; Steen, Virginia; A. Read, Charles; D. Mayes, Maureen; Parsley, Ed; K. Mubarak, Kamal; Kari Connolly, M.; A. Golden, Jeffrey; A. Olman, Mitchell; J. Fessler, Barri; F. Rothfield, Naomi; L. Metersky, Mark

doi:10.1056/nejmoa055120

Public

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Published in New England Journal of Medicine • Jun 21, 2006

Authors:

Donald P. Tashkin

Robert M. Elashoff

Philip J. Clements

Abstract

BACKGROUND: We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease. METHODS: At 13 clinical cente...

Subject

Medicine

Cyclophosphamide

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!